![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00435838 |
This is a retrospective observational study which follows on from CNA106030 (a study evaluating whether prospective genetic screening for HLA-B*5701 can reduce the incidence of hypersensitivity reactions to abacavir). This study aims to collect data on approximately 35 subjects who withdrew from CNA106030 when found to be HLA-B*5701 positive. HIV disease management and adverse event data in these subjects, where the risk/benefit ratio of treatment with abacavir may alter subsequent prescribing, will be collected
Condition | Intervention |
---|---|
HIV Infection |
Drug: No Intervention -- Observational study |
Study Type: | Observational |
Study Design: | Retrospective |
Official Title: | A Retrospective, Multi-Centre Observational Study to Evaluate Disease Management and Adverse Events in Adult Subjects With HIV-1 Infection Who Were Withdrawn From CNA106030 Due to a Positive HLA-B*5701 Test Result |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion criteria:
Austria | |
GSK Investigational Site | |
Vienna, Austria, A-1140 | |
GSK Investigational Site | |
Vienna, Austria, A-1090 | |
GSK Investigational Site | |
Salzburg, Austria, A-5020 | |
GSK Investigational Site | |
Innsbruck, Austria, A-6020 | |
GSK Investigational Site | |
Graz, Austria, A-8020 | |
Belgium | |
GSK Investigational Site | |
Bruxelles, Belgium, 1000 | |
GSK Investigational Site | |
Brussels, Belgium, 1070 | |
Italy, Emilia-Romagna | |
GSK Investigational Site | |
Rimini, Emilia-Romagna, Italy, 47900 | |
Italy, Lazio | |
GSK Investigational Site | |
Roma, Lazio, Italy, 00185 | |
Italy, Lombardia | |
GSK Investigational Site | |
Milano, Lombardia, Italy, 20142 | |
GSK Investigational Site | |
Legnano (MI, Lombardia, Italy, 20025 | |
Italy, Trentino-Alto Adige | |
GSK Investigational Site | |
Bolzano, Trentino-Alto Adige, Italy, 39100 | |
Italy, Veneto | |
GSK Investigational Site | |
Padova, Veneto, Italy, 35128 | |
Russian Federation | |
GSK Investigational Site | |
Volgograd, Russian Federation, 400040 | |
GSK Investigational Site | |
Orel, Russian Federation, 302040 | |
GSK Investigational Site | |
Belgorod, Russian Federation, 308036 | |
Slovenia | |
GSK Investigational Site | |
Ljubljana, Slovenia, 1000 | |
Spain | |
GSK Investigational Site | |
Barcelona, Spain, 08907 | |
GSK Investigational Site | |
Madrid, Spain, 28041 | |
GSK Investigational Site | |
Badalona, Spain, 08916 | |
GSK Investigational Site | |
Alicante, Spain, 03010 | |
GSK Investigational Site | |
Valencia, Spain, 46015 | |
GSK Investigational Site | |
Alcala de Henares, Spain, 28805 | |
GSK Investigational Site | |
Malaga, Spain, 29020 | |
Switzerland | |
GSK Investigational Site | |
La Chaux-de-Fonds, Switzerland, CH 2301 |
Study Director: | GSK Clinical Trials, PhD | GlaxoSmithKline |
Responsible Party: | GSK ( Study Director ) |
Study ID Numbers: | CNA108223 |
Study First Received: | February 15, 2007 |
Last Updated: | October 13, 2008 |
ClinicalTrials.gov Identifier: | NCT00435838 |
Health Authority: | Italy: Ministry of Health |
HLa-B*5701
Abacavir |
Virus Diseases Sexually Transmitted Diseases, Viral HIV Infections Sexually Transmitted Diseases |
Acquired Immunodeficiency Syndrome Abacavir Retroviridae Infections Immunologic Deficiency Syndromes |
Communicable Diseases RNA Virus Infections Slow Virus Diseases |
Immune System Diseases Lentivirus Infections Infection |